home / stock / bctxf / bctxf news

BCTXF News and Press, BriaCell Therapeutics From 08/11/20

Stock Information
Company Name: BriaCell Therapeutics
Stock Symbol: BCTXF
Market: OTC
Website: briacell.com
Menu
BCTXF BCTXF Quote BCTXF Short BCTXF News BCTXF Articles BCTXF Message Board
Get BCTXF Alerts

News, Short Squeeze, Breakout and More Instantly...
BCTXF - Briacell Therapeutics Corp. Announces Shares for Debt Issuance

BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that...
BCTXF - BriaCell files provisional patent for treatment and diagnosis of COVID-19

BriaCell Therapeutics ( OTCQB:BCTXF ) has filed a provisional patent application with the USPTO, entitled “MULTI-VALENT DECOY RECEPTORS FOR DIAGNOSIS AND/OR TREATMENT OF CORONAVIRUS INFECTION”. More news on: Briacell Therapeutics Corp., Healthcare stocks news, Read more...

BCTXF - BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease

BERKELEY, Calif. and VANCOUVER, British Columbia, June 24, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced b...

BCTXF - BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting

Preliminary safety and efficacy data is being presented today from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. Clinical responses and disease control—without serious side effect...
BCTXF - BriaCell CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June

BERKELEY, Calif. and VANCOUVER, British Columbia, June 09, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced b...

BCTXF - BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) Meeting

Preliminary safety and efficacy data is being presented on May 29 at 9:00 a.m. ET from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: Lead candidate, Bria-IMT™, with or without a PD-1 inhibitor, s...

BCTXF - BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications

BERKELEY, Calif. and VANCOUVER, British Columbia, May 20, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced br...
BCTXF - BriaCell Announces Presentation and Abstract Publication at 2020 American Society of Clinical Oncology (ASCO) Meeting

New data and pathological findings on BriaCell’s lead candidate, Bria-IMT™, to be Highlighted at ASCO 2020 in a Poster Presentation BERKELEY, Calif. and VANCOUVER, British Columbia, May 14, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell”...

BCTXF - BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic

Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, for breast cancer treatment, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic. BriaCell is currently evaluatin...

BCTXF - BriaCell Files Patent Application for Novel Therapeutics for Cancer

BERKELEY, Calif., and VANCOUVER, British Columbia, April 27, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced...
Previous 10 Next 10